Highlights

  • TruScreen appointed Albatros Health Care as its Uzbekistan distributor.
  • A pilot cervical cancer screening study involving around 600 participants is expected to begin in Tashkent.
  • The expansion could generate sales Revenue potential of USD740,000 through 2028.

Overview

TruScreen Group Limited (NZX:TRU) has expanded its Central Asian presence by appointing Albatros Health Care LLC as its distributor in Uzbekistan while progressing a pilot clinical study in Tashkent. The study is expected to support the rollout of TruScreen’s AI-enabled cervical cancer screening technology across both public and private healthcare settings. The company believes Uzbekistan presents a significant growth opportunity due to its large screening-age female population and increasing focus on cervical cancer prevention. TruScreen also expects the initiative to strengthen its position in emerging healthcare markets across the wider Central Asian region.

Why Is Uzbekistan Important for TruScreen’s Expansion Strategy?

Uzbekistan represents a strategic healthcare market for TruScreen due to rising Demand for scalable cervical cancer screening solutions. The country has a large population of women within the screening age bracket, while cervical cancer remains one of the most common cancers among women. TruScreen’s real-time screening technology is designed to provide immediate results and improve accessibility in regions where traditional screening infrastructure may be limited.

The appointment of Albatros Health Care strengthens TruScreen’s market-entry strategy through local distribution expertise and established government relationships. The distributor’s nationwide healthcare network is expected to support Training, commercial rollout, and broader adoption of TruScreen’s screening technology across Uzbekistan.

How Could the Pilot Clinical Study Support Wider Adoption?

The pilot clinical study in Tashkent is expected to provide validation data comparing TruScreen’s technology with traditional Pap smear testing methods. The study aims to assess screening accuracy, operational efficiency, and implementation requirements within local healthcare settings. Results from the program could help support broader adoption across both public and private healthcare sectors in Uzbekistan.

TruScreen believes the study may also contribute toward the development of a national cervical cancer screening program in the country. Senior clinical managers from the company will assist with training and implementation activities ahead of the planned commercial launch. The initiative aligns with TruScreen’s strategy of expanding through local partnerships in emerging healthcare markets.